The value of plasma levels of tumor necrosis factor-α and interleukin-6 in predicting the severity and prognosis in patients with congestive heart failure

Journal of the Chinese Medical Association

Volumn 67, Issue 5, 2004, Pages 222-228

  Pan, Jun Pin ^a,b   Liu, Tu Ying ^a   Chiang, Shu Chiung ^a   Lin, Yung Kuo ^a   Chou, Chia Yea ^a   Chan, Wan Leong ^a,b   Lai, Shiau Tung ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Congestive heart failure; Cytokines; Interleukin 6; Tumor necrosis factor

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASODILATOR AGENT;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD LEVEL; BODY MASS; CARDIOMYOPATHY; CASE CONTROL STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART DEATH; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RATE; HEART VENTRICULOGRAPHY; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PATIENT CODING; PREDICTION; SYSTOLIC BLOOD PRESSURE; VALVULAR HEART DISEASE;

AGED; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 4043174256     PISSN: 17264901     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Mann DL, Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of pro-inflammatory cytokines. Chest 1994;105:897-904.
2. Munger M, Johnson B, Amber I, Callahan KS, Gilbert EM. Circulating concentrations of pro-inflammatory cytokines in mild or moderate heart failure secondary to ischemic or IDC. Am J Cardiol 1996;77:723-7.
3. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41.
4. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Pro-inflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the SOLVD study. J Am Coll Cardiol 1996;27:1201-6.
5. Genth-Zotz S, von Haehling S, Bolger AP, Kalra PR, Wensel R, Coats AJ, Anker SD. Pathophysiologic quantities of endotoxin- induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am J Cardiol 2002;90:1226-30.
6. Neumann F-J, Ott I, Gawaz M, Richardt G, Holzapfel H, Jochum M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995;92:748-55.
7. Ghezzi P, Dinarello CA, Biamchi M, Rosamdich ME, Repine JE, White CW. Hypoxia increases production of interleukin-1 and tumor-necrosis-factor by mononuclear cells. Cytokine. 1991;3:189-94.
8. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704-11.
9. Kishimoto T. The biology of interleukin-6. Blood 1989;74: 1-10.
10. Jirik FR, Podor TJ, Hirano T, Kishimoto T, Loskutoff DJ, Carson DA, Lotz M. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol 1989;142:144-7.
11. Loppnow H, Libby P. Functional significance of human vascular smooth muscle cell-derived interleukin 1 in paracrine and autocrine regulation pathways. Exp Cell Res. 1992;198: 283-90.
12. Bradham WS, Bozkurt B, Gunasinghe H, Mann D, Spinale FG. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res 2002;53:822-30.
13. Tsujinaka T, Ebisui C, Fujita J, Kishibuchi M, Morimoto T, Ogawa A, et al. Muscle undergoes atrophy in association with increase of lysosomal cathepsin activity in interleukin-6 transgenic mouse. Biochem Biophys Res Commun 1995;207:168-74.
14. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RE. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9.
15. Wiedermann CJ, Beimpold H, Herold M, Knapp E, Braunsteiner H. Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. J Am Coll Cardiol 1993;22:1897-901.
16. Katz SD, Rao R, Berman JW, Schwarz M, Demopoulos L, Bijou R, et al. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure: relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 1994;90:12-6.
17. Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman J, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996;28:964-71.
18. Mann DL. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol 2003;65:81-101.
19. Sharma R, Bolger AP, Li W, Davlouros PA, Volk HD, Poole-Wilson PA, et al. Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. Am J Cardiol 2003;92:188-93.
20. Yamaoka M, Yamaguchi S, Okuyama M, Tomoike H. Anti-inflammatory cytokine profile in human heart failure: behavior of interleukin-10 in association with tumor necrosis factor-alpha. Jap Circ J 1999;63:951-6.
21. Aukrust P, Ueland T, Lien E, Bendtzen K, Muller F, Andreassen AK, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1999;83:376-82.
22. Dibbs Z, Thornby J, White BG, Mann DL. Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. J Am Coll Cardiol 1999;33:1935-42.
23. Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumor necrosis factor α in severe congestive heart failure. Br Heart J 1993;70:141-3.
24. Aker S, Belosjorow S, Konietzka I, Duschin A, Martin C, Heusch G, Schulz R. Serum but not myocardial TNF-alpha concentration is increased in pacing-induced heart failure in rabbits. Am J Physiol Regul Integr Comp Physiol 2003;285: R463-9.
25. Xin X, Cai Y, Matsumoto K, Agui T. Endothelin-induced interleukin-6 production by rat aortic endothelial cells. Endocrinology 1995;136:132-7.
26. Ohkawa F, Ikeda U, Kanbe T, Kawasaki K, Shimada K. Effects of inflammatory cytokines on vascular tone. Cardiovasc Res 1995;30:711-5.
27. Eriksson U, Kurrer MO, Schmitz N, Marsch SC, Fontana A, Eugster HP, Kopf M. Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3. Circulation 2003;107:320-5.
28. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998;31:391-8.
29. Sato Y, Takatsu Y, Kataoka K, Yamada T, Taniguchi R, Sasayama S, et al. Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol 1999;22:811-3.
30. Liu L, Zhao SP. The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy. Int J Cardiol 1999;69:77-82.
31. Sharma R, Rauchhaus M, Ponikowski PP, Varney S, Poole-Wilson PA, Mann DL, et al. The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2000;36:523-8.
32. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 2000;35:714-21.
33. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999;99:3224-6.
34. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107: 3133-40.
35. Poehlman ET, Danforth E. Endurance training increases metabolic rate and norepinephrine appearance rate in older individuals. Am J Physiol 1991;261:E233-9.
36. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin: studies on body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 1989;80:299-305.
37. Stefan DA, Tuan PC, Piotr P, Derrek H, Jon WS, Wolfgang JK, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96:526-34.
38. Swan JW, Walton C, Godsland IF, Clark AL, Coats AJS, Oliver MF. Insulin resistance in chronic heart failure. Eur Heart J 1994;15:1528-32.